Phase 3 N=768 A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain
Acute Pain
Primary: Number of Patients That Experienced a Treatment-emergent Adverse Event — 490 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=224 A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Tuberous Sclerosis Complex · Seizures
Primary: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) — -43.36…
Phase 3 N=379 A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Head Lice Infestation
Primary: Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit. — 43; 28 participants
Phase 3 N=33 Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
Bilateral Middle Ear Effusion
Primary: Otoscopic Examination: Auricle and Meatus — 1 ears
Phase 3 N=3,270 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
HER2/Neu Positive · Progesterone Receptor Positive · Recurrent Breast Carcinoma
Primary: Percentage of Patients Alive and Free From Invasive Disease (IDFS) — 89.2; 89.8 percentage of patients
Phase 3 N=262 Phase 3 Study of OTO-201 in Acute Otitis Externa
Acute Otitis Externa · Swimmer's Ear
Primary: Number of Subjects Considered a Clinical Cure at Day 8 — 91; 63 Participants
Phase 3 N=27 CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
Primary Immunodeficiency
Primary: Occurrence of All Treatment-emergent Adverse Events (TEAEs) — 8; 19; 22; 155 events
Phase 3 N=466 A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
Acne Vulgaris
Primary: Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12 — 13.95; 11.15 Lesion counts — p=0.0083
Phase 3 N=501 Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes
Otitis Media
Primary: Number of Subjects With Post-surgical Otorrhea — 383; 118 Participants
Phase 3 N=377 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
Hepatitis C
Primary: Percentage of Participants Who Maintained a Sustained Virologic Response (SVR) Out of Those Who Achieved SVR12 in a Prior Study With an ABT-493- and/or…
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
Phase 3 N=501 Vitamin C, Thiamine, and Steroids in Sepsis
Sepsis
Primary: Vasopressor and Ventilator-free Days (VVFD) — 25; 26 days
Phase 3 N=301 Treatment of Patients With Nocturia
Nocturia
Primary: Change in Mean Number of Nocturic Episodes/Night — -1.3; -1.2 nocturic episodes per night
Phase 3 N=296 A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
Head Lice
Primary: The Proportion of Index Subjects Who Are Lice Free at Day 15 — 106; 98; 7 Participants
Phase 3 N=376 Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain
Osteoarthritis · Low Back Pain
Primary: Summary of Adverse Events (AEs) — 235; 17; 200; 4 Participants